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Humans vary substantially in their willingness to take risks. In a combined sample of over 1 million individuals, we con-
ducted genome-wide association studies (GWAS) of general risk tolerance, adventurousness, and risky behaviors in the 
driving, drinking, smoking, and sexual domains. Across all GWAS, we identified hundreds of associated loci, including 99 
loci associated with general risk tolerance. We report evidence of substantial shared genetic influences across risk toler-
ance and the risky behaviors: 46 of the 99 general risk tolerance loci contain a lead SNP for at least one of our other GWAS, 
and general risk tolerance is genetically correlated ( rg∣ ̂ ∣  ~ 0.25 to 0.50) with a range of risky behaviors. Bioinformatics 
analyses imply that genes near SNPs associated with general risk tolerance are highly expressed in brain tissues and point 
to a role for glutamatergic and GABAergic neurotransmission. We found no evidence of enrichment for genes previously 
hypothesized to relate to risk tolerance.
Genome-wide association analyses of risk tolerance  
and risky behaviors in over 1 million individuals  
identify hundreds of loci and shared genetic influences
Choices in important domains of life, including health, fer-tility, finance, employment, and social relationships, rarely have consequences that can be anticipated perfectly. The 
degree of variability in possible outcomes is called risk. Risk toler-
ance—defined as the willingness to take risks, typically to obtain 
some reward—varies substantially across humans and has been 
actively studied in the behavioral and social sciences. An individu-
al’s risk tolerance may vary across domains, but survey-based mea-
sures of general risk tolerance (for example, ‘Would you describe 
yourself as someone who takes risks?’) have been found to be good 
all-around predictors of risky behaviors such as portfolio alloca-
tion, occupational choice, smoking, drinking alcohol, and starting 
one’s own business1–3.
Twin studies have established that various measures of risk toler-
ance are moderately heritable (h2 ~ 30%, although estimates in the 
literature vary3–5). Discovery of specific genetic variants associated 
with general risk tolerance could provide insights into underlying 
biological pathways, advance understanding of how genetic influ-
ences are amplified and dampened by environmental factors, enable 
the construction of polygenic scores (indexes of many genetic vari-
ants) that can be used as overall measures of genetic influences on 
individuals, and help distinguish genetic variation associated with 
general versus domain-specific risk tolerance.
Although risk tolerance has been one of the most studied pheno-
types in social science genetics, most claims of positive findings have 
been based on small-sample candidate gene studies (Supplementary 
Table 1), whose limitations are now appreciated6. To date, only two 
loci associated with risk tolerance have been identified in GWAS7,8.
Here, we report results from large-scale GWAS of self-
reported general risk tolerance (our primary phenotype) and six 
supplementary phenotypes: ‘adventurousness’ (defined as the 
self-reported tendency to be adventurous versus cautious); four 
risky behaviors: ‘automobile speeding propensity’ (the tendency 
to drive faster than the speed limit), ‘drinks per week’ (the average 
number of alcoholic drinks consumed per week), ‘ever smoker’ 
(whether one has ever been a smoker), and ‘number of sexual 
partners’ (the lifetime number of sexual partners); and the first 
principal component (PC) of these four risky behaviors, which 
we interpret as capturing the general tendency to take risks across 
domains. All seven phenotypes are coded such that higher pheno-
type values are associated with higher risk tolerance or risk tak-
ing. Table 1 lists, for each GWAS, the datasets we analyzed and the 
GWAS sample sizes.
Results
Association analyses. All seven GWAS were performed in 
European-ancestry subjects, included controls for the top ten 
(or more) PCs of the genetic relatedness matrix and for sex and 
birth year (Supplementary Table 2), and followed procedures 
described in a prespecified analysis plan (see URLs) and in the 
Supplementary Note.
In the discovery phase of our GWAS of general risk tolerance 
(n = 939,908), we conducted a GWAS by using the UK Biobank 
(UKB; n = 431,126) and then performed a sample-size-weighted 
meta-analysis of those results with GWAS results from a sample 
of research participants from 23andMe (n = 508,782). The UKB 
measure of general risk tolerance is based on the question ‘Would 
you describe yourself as someone who takes risks? Yes/No’. The 
23andMe measure is based on a question about overall comfort tak-
ing risks, with five response options ranging from ‘very comfortable’ 
to ‘very uncomfortable’. The genetic correlation9 between the UKB 
and 23andMe cohorts ( ̂rg = 0.77, s.e. = 0.02) is < 1 but large enough 
to justify our approach of pooling the two cohorts (see Section 2 in 
the Supplementary Note of ref. 10 for a theoretical demonstration 
of the merits of pooling cohorts despite moderate heterogeneity of 
phenotype measures).
The quantile–quantile (Q–Q) plot (Supplementary Fig. 1a) from 
the discovery GWAS exhibited substantial inflation (λGC = 1.41). 
According to the estimated intercept from a linkage disequilibrium 
(LD) score regression11, only a small share of this inflation (~5%) in 
test statistics was due to confounding biases such as cryptic related-
ness and population stratification. To account for these biases, we 
inflated GWAS standard errors by the square root of the LD score 
regression intercept11.
A full list of authors and affiliations appears at the end of the paper.
NatuRe GeNetics | VOL 51 | FEBRUARY 2019 | 245–257 | www.nature.com/naturegenetics 245
Articles Nature GeNetics
We identified 124 approximately independent SNPs (pairwise 
r2 < 0.1) that attained genome-wide significance (P < 5 × 10–8). These 
124 ‘lead SNPs’ are listed in Supplementary Table 3 and are shown 
in Fig. 1a. All had coefficients of determination (R2 values) below 
0.02%, and the SNP with the largest per-allele effect was estimated 
to increase general risk tolerance by ~0.026 standard deviations in 
our discovery sample (Supplementary Fig. 2). To test whether the 
lead SNPs’ effect sizes were heterogeneous across the 23andMe 
and UKB cohorts, we generated an omnibus test statistic by sum-
ming Cochran’s Q statistics across all lead SNPs; in agreement 
with our genetic correlation estimate of less than unity between 
the two cohorts, we rejected the null hypothesis of homogene-
ity (P = 4.32 × 10–5; Supplementary Note). To define genomic loci 
around the lead SNPs, we took the physical regions containing all 
SNPs in LD (pairwise r2 > 0.6) with the lead SNPs and merged loci 
within 250 kb of each other; the 124 lead SNPs were located in 99 
such loci (Supplementary Table 3). We supplemented those analyses 
with a conditional and joint multiple-SNP (COJO) analysis12, which 
identified 91 genome-wide-significant ‘conditional associations’ 
(Supplementary Table 3).
In the replication phase of our GWAS of general risk tolerance 
(combined n = 35,445), we meta-analyzed summary statistics from 
ten smaller cohorts. Additional details on cohort-level phenotype 
measures are provided in Supplementary Table 4. The cohorts’ sur-
vey questions differed in terms of their exact wording and number 
of response categories, but all questions asked subjects about their 
overall or general attitudes toward risk. The genetic correlation9 
between the discovery and replication GWAS was 0.83 (s.e. = 0.13). 
Of the 124 lead SNPs, 123 were available or well proxied by an avail-
able SNP in the replication GWAS results. Out of these 123 SNPs, 94 
had a concordant sign (P = 1.7 × 10–9), and 23 were significant at the 
5% level in one-tailed t tests (P = 4.5 × 10–8) (Supplementary Fig. 3). 
This empirical replication record closely matched theoretical pro-
jections that take into account sampling variation and the winner’s 
curse (Supplementary Note).
In the UKB, we tested and confirmed that a much higher frac-
tion of males (34%) than females (19%) described themselves 
as risk tolerant on the general risk tolerance measure (t-test 
P < 1 × 10−100; Supplementary Fig. 4), a result consistent with much 
prior research13,14. We used bivariate LD score regression to calcu-
late the genetic correlation between GWAS performed separately 
in the sample of females and in the sample of males in the UKB. 
Our estimate ( ̂rg = 0.822, s.e. = 0.033) was high enough to justify 
our approach of pooling males and females in our other analyses to 
maximize statistical power10. Nonetheless, our estimate was signifi-
cantly smaller than unity, suggesting that the autosomal genetic fac-
tors contributing to general risk tolerance, although largely similar 
across sexes, are not identical.
Our six supplementary GWAS—of adventurousness, the 
four risky behaviors, and their PC (n = 315,894 to 557,923; 
Supplementary Tables 4 and 5)—were conducted by using meth-
ods comparable to those in the primary GWAS, except that they 
had no replication phases, and most involved a single large cohort. 
Supplementary Fig. 1 shows Q–Q plots, and Supplementary Fig. 5 
shows Manhattan plots.
Table 1 provides a summary overview of the seven GWAS. We 
identified a total of 864 ‘lead associations’: the sum total of the 124 
general-risk-tolerance lead SNPs together with the 740 lead SNPs 
from the six supplementary GWAS. (These 864 lead associations 
were obtained by considering each of our seven phenotypes sepa-
rately and using the standard genome-wide-significance P-value 
threshold of 5 × 10–8. When we instead considered the seven GWAS 
jointly and use a Bonferroni-corrected P-value threshold of 7.1 × 10−9 
(5 × 10−8/7), we obtained 566 lead associations across the seven 
GWAS.) Because we did not have the data to conduct replication 
analyses of the lead associations from the supplementary GWAS, 
we calculated the maxFDR15, a theoretical upper bound on the false 
discovery rate (FDR), for each GWAS. The maxFDR estimates were 
low across all GWAS (the highest estimate was 1.22 × 10−3, for auto-
mobile speeding propensity), thus providing reassurance about the 
robustness of the lead associations.
Applying our locus definition, we identified a total of 703 
‘locus associations’: the sum total of the 99 general-risk-tolerance 
loci together with the 604 loci from the supplementary GWAS 
(Supplementary Note). Pooling the loci corresponding to the 703 
locus associations, and merging loci within 250 kb of each other, 
yielded 444 distinct loci. COJO analyses12 identified a sum total 
of 655 conditional associations across all seven GWAS. (When we 
instead considered the seven GWAS jointly and used a Bonferroni-
corrected P-value threshold of 7.1 × 10−9 (5 × 10−8/7), we obtained 
464 locus associations and 505 conditional associations across the 
seven GWAS.) We verified that the results of the COJO analyses 
were consistent with those from multiple regressions, using indi-
vidual-level genotype-dosage data from the UKB (Supplementary 
Note). Supplementary Tables 3, 6, and 7 report the lead SNPs, the 
genomic loci, and the results of the COJO analyses. Table 1 also 
shows the SNP heritabilities16 of the seven phenotypes, calculated 
from the GWAS results; the SNP heritabilities ranged from ~0.05 
(for general risk tolerance) to ~0.16 (for the first PC of the four risky 
behaviors).
We note that 212 of the 864 lead associations were located within 
long-range LD regions17 or candidate inversions (that is, genomic 
regions highly prone to inversion polymorphisms; Supplementary 
Note). Of these, only 109 were also conditional associations, and 46 
were in loci containing no conditional associations, thus indicat-
ing that many lead associations in the long-range LD regions and 
candidate inversions may tag causal variants that are also tagged by 
other lead associations. We discuss some of these regions in the next 
section.
Genetic overlap. There was substantial overlap across the results 
of our GWAS. For example, 46 of the 99 general-risk-tolerance loci 
contained a lead SNP of at least one of the other GWAS, and 72 of 
the 124 general-risk-tolerance lead SNPs were in weak LD (pair-
wise r2 > 0.1) with a lead SNP of at least one of the other GWAS 
(including 45 for adventurousness and 49 for at least one of the four 
risky behaviors or their first PC). To empirically assess whether this 
overlap could be attributed to chance, we conducted resampling 
exercises under the null hypothesis that the lead SNPs of our sup-
plementary GWAS were distributed independently of the general-
risk-tolerance loci and lead SNPs. We strongly rejected this null 
hypothesis (P < 0.0001; Supplementary Note).
Several long-range LD regions, candidate inversions, and LD 
blocks18 stood out for being associated both with general risk tol-
erance and with all or most of the supplementary phenotypes. We 
tested whether the signs of the lead SNPs located in these regions 
tended to be concordant across our primary and supplementary 
GWAS. We strongly rejected the null hypothesis of no concor-
dance (P < 3 × 10–30; Supplementary Note), suggesting that these 
regions represent shared genetic influences, rather than colocal-
ization of causal SNPs. Figure 1b and Supplementary Fig. 6 show 
local Manhattan plots for some of these long-range LD regions and 
candidate inversions. The long-range LD region17 on chromosome 
3 (~83.4 to 86.9 Mb) contained lead SNPs from all seven GWAS as 
well as the most significant lead SNP from the general-risk-toler-
ance GWAS, rs993137 (P = 2.14 × 10–40), which is located in the gene 
CADM2. Another long-range LD region, on chromosome 6 (~25.3–
33.4 Mb), covers the HLA complex and contained lead SNPs from 
all GWAS except drinks per week. Three candidate inversions on 
chromosomes 7 (~124.6–132.7 Mb), 8 (~7.89–11.8 Mb), and 18 
(~49.1–55.5 Mb) contained lead SNPs from six, five, and all seven 
of our GWAS, respectively. Finally, four other LD blocks18 that did 
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not overlap known long-range LD or candidate inversion regions 
each contained lead SNPs from five of our GWAS (including general 
risk tolerance). Although many of the lead SNPs in these regions 
were not conditional associations, the above results regarding the 
numbers of GWAS with lead SNPs in these regions also held when 
we considered only the conditional associations instead of the lead 
SNPs in those regions. The two long-range LD regions and the three 
candidate inversions have been found to be associated with numer-
ous phenotypes, including many cognitive and neuropsychiatric 
phenotypes19.
To investigate genetic overlap at the genome-wide level, we esti-
mated genetic correlations with self-reported general risk tolerance 
by using bivariate LD score regression9. (For this and all subse-
quent analyses involving general risk tolerance, we used the sum-
mary statistics from the combined meta-analysis of our discovery 
and replication GWAS.) The estimated genetic correlations with 
our six supplementary phenotypes were all positive, larger than 
~0.25, and highly significant (P < 2.3 × 10–30; Fig. 2), indicating that 
SNPs associated with higher general risk tolerance also tend to be 
associated with riskier behavior. The largest estimated genetic cor-
relations were with adventurousness ( ̂rg = 0.83, s.e. = 0.01), number 
of sexual partners (0.52, s.e. = 0.02), automobile speeding propen-
sity (0.45, s.e. = 0.02), and the first PC of the four risky behaviors 
(0.50, s.e. = 0.02).
Our estimates of the genetic correlations between general 
risk tolerance and the supplementary risky behaviors were sub-
stantially higher than the corresponding phenotypic correlations 
(Supplementary Tables 8 and 9). Although measurement error 
partly accounts for the low phenotypic correlations, the genetic 
correlations remained considerably higher even after adjustment 
of the phenotypic correlations for measurement error. The com-
paratively large genetic correlations support the view that a general 
factor of risk tolerance partly accounts for cross-domain correla-
tion in risky behavior20,21 and imply that this factor is genetically 
influenced. The lower phenotypic correlations suggest that envi-
ronmental factors are more important contributors to domain-
specific risky behavior22,23.
To increase the precision of our estimates of the SNPs’ effects 
on general risk tolerance, we leveraged the high degree of genetic 
overlap across our phenotypes by conducting multitrait analysis 
of GWAS (MTAG)15. We used as inputs the summary statistics of 
our GWAS of general risk tolerance, of our first five supplementary 
GWAS (that is, not including the first PC of the four risky behav-
iors), and of a previously published GWAS on lifetime cannabis 
use24 (Supplementary Note). MTAG increased the number of gen-
eral-risk-tolerance lead SNPs from 124 to 312 (Supplementary Fig. 7 
and Supplementary Table 10).
We also estimated genetic correlations between general risk tol-
erance and 28 additional phenotypes (Fig. 2 and Supplementary 
Table 9). These included phenotypes for which we could obtain 
summary statistics from previous GWAS, as well as five phenotypes 
for which we conducted new GWAS. The estimated genetic corre-
lations for the personality traits extraversion ( ̂rg = 0.51, s.e. = 0.03), 
neuroticism (–0.42, s.e. = 0.04), and openness to experience (0.33, 
s.e. = 0.03) were significantly distinguishable from zero after 
Bonferroni correction and were substantially larger in magnitude 
than previously reported phenotypic correlations25, thus point-
ing to shared genetic influences among general risk tolerance and 
these traits. After Bonferroni correction, we also found significant 
positive genetic correlations with the neuropsychiatric phenotypes 
attention deficit hyperactivity disorder (ADHD), bipolar disorder, 
and schizophrenia. When viewed in light of the genetic correlations 
we found with some supplementary phenotypes and additional 
risky behaviors classified as externalizing (for example, substance 
use, elevated sexual behavior, and fast driving), these results suggest 
the hypothesis that the overlap with the neuropsychiatric pheno-
types is driven by their externalizing component26.
Polygenic prediction. We constructed polygenic scores of gen-
eral risk tolerance to gauge their potential usefulness in empirical 
research (Supplementary Note). We used the Add Health, HRS, 
NTR, STR, UKB-siblings, and Zurich cohorts as validation cohorts 
(Supplementary Table 5 provides an overview of these cohorts; the 
UKB-siblings cohort comprised individuals with at least one full 
sibling in the UKB). For each validation cohort, we constructed 
the score using summary statistics from a meta-analysis of our 
discovery and replication GWAS that excluded the cohort (for the 
UKB-siblings cohort, we reran our UKB GWAS after excluding 
individuals from that cohort). Our measure of predictive power 
was the incremental R2 (or pseudo-R2) from adding the score to a 
Table 1 | GWas results









General risk tolerance  
(disc. GWAS)
UKB; 23andMe 939,908 1.85 1.04 (0.01) 124 99 91 0.046 (0.001)
General risk tolerance  
(repl. GWAS)
10 indep. cohorts 35,445 1.03 1.00 (0.07) 0 0 0 –
General risk tolerance  
(disc. + repl.)
UKB; 23andMe; 10 
indep. cohorts
975,353 1.87 1.04 (0.01) 132 107 97 0.045 (0.001)
Adventurousness 23andMe 557,923 1.98 1.05 (0.01) 167 137 126 0.098 (0.002)
Automobile speeding 
propensity
UKB 404,291 1.53 1.03 (0.01) 42 36 33 0.079 (0.003)
Drinks per week UKB 414,343 1.61 1.03 (0.01) 85 62 61 0.085 (0.003)
Ever smoker UKB; TAG Consortium43 518,633 1.97 1.05 (0.01) 223 183 172 0.109 (0.003)
Number of sexual partners UKB 370,711 1.77 1.04 (0.01) 117 97 88 0.128 (0.003)
First PC of the four risky 
behaviors
UKB 315,894 1.77 1.05 (0.01) 106 89 84 0.156 (0.004)
The table provides an overview of the GWAS of our primary and supplementary phenotypes. Replication analysis of the lead SNPs’ association results in independent cohorts was conducted only for 
the discovery GWAS of general risk tolerance. n, GWAS sample size; mean χ2, mean GWAS χ2 statistics across HapMap3 SNPs with MAF greater than 0.01; LD score intercept, estimate of the intercept 
from a LD score regression11 using HapMap3 SNPs with MAF greater than 0.01; no. lead SNPs, number of approximately independent (pairwise r2 < 0.1) lead SNPs; no. loci, number of associated loci; no. 
cond. assoc., number of conditional associations in the COJO analysis12; SNP h2, SNP heritability estimated with the HESS method16 using 1000 Genomes phase 3 SNPs with MAF greater than 0.05; disc., 
discovery; repl., replication; indep., independent.
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regression of the phenotype on controls for sex, birth year, and the 
top ten PCs of the genetic relatedness matrix.
Our preferred score was constructed with LDpred27. Our larg-
est validation cohort (n ~ 35,000) was the UKB-siblings cohort. 
In that validation cohort, the score’s predictive power was 1.6% 
for general risk tolerance, 1.0% for the first PC of the four risky 
behaviors, 0.8% for number of sexual partners, 0.6% for automo-
bile speeding propensity, and ~0.15% for drinks per week and 
ever smoker. Across our validation cohorts, in which other phe-
notypes were measured, the score was also predictive of several 
personality phenotypes and a suite of real-world measures of risky 
behaviors in the health, financial, and career domains, and others 
(Supplementary Figs. 8 and 9 and Supplementary Tables 11–14). 
The incremental R2 observed for general risk tolerance was con-
sistent with our theoretical prediction, given the GWAS sample 
sizes, the SNP heritability of general risk tolerance (Table 1), and 
the imperfect genetic correlations across the GWAS and validation 
cohorts28,29 (Supplementary Note).
Biological annotation. To gain insights into the biological mecha-
nisms through which genetic variation influences general risk toler-
ance, we conducted a number of bioinformatics analyses by using 
the results of the combined meta-analysis of our discovery and rep-
lication GWAS of general risk tolerance.
First, we systematically reviewed the literature that aimed to 
link risk tolerance to biological pathways (Supplementary Note). 
Our review covered studies based on candidate genes (that is, 
specific genetic variants used as proxies for biological pathways), 
pharmacological manipulations, biochemical assays, and genetic 
manipulations in rodents, as well as other research designs. Our 
review identified 132 articles that matched our search criteria 
(Supplementary Table 1). This previous work has focused on five 
main biological pathways: the steroid hormone cortisol, the mono-
amines dopamine and serotonin, and the steroid sex hormones 
estrogen and testosterone. Using a MAGMA30 competitive gene-set 
analysis, we found no evidence that SNPs within genes associated 
with these five pathways tended to be more associated with general 
risk tolerance than SNPs in other genes (Supplementary Table 15). 
Furthermore, none of the other bioinformatics analyses reported 
below point to these pathways.
We also examined the 15 most commonly tested autosomal genes 
within the dopamine and serotonin pathways, which were the focus 
of most of the 34 candidate-gene studies identified by our literature 
review. We verified that the SNPs available in our GWAS results 
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Fig. 1 | Manhattan plots. In all panels, the x axis is chromosomal position; the y axis is the GWAS P value on a − log10 scale (based on a two-tailed z test); 
each lead SNP is marked by a red × ; each conditional association is marked by a red ○ ; and each SNP that is both a lead SNP and a conditional association 
is marked by a red ⊗ . a, Manhattan plots for the discovery GWAS of general risk tolerance (n =  939,908). b, Local Manhattan plots of a long-range LD 
region on chromosome 3 and a candidate inversion on chromosome 18 that contained lead SNPs for all seven of our GWAS. The gray background marks 
the locations of long-range LD or candidate inversion regions. c, Local Manhattan plots of the areas around the 15 most commonly tested candidate genes 
in the prior literature on the genetics of risk tolerance. Each local plot shows all SNPs within 500 kb of the gene’s borders that were in weak LD (r2 > 0.1) 
with a SNP in the gene. The 15 plots are concatenated and shown together in the panel, divided by black vertical lines. The 15 genes were not particularly 
strongly associated with general risk tolerance or the risky behaviors, as can be seen by comparing the results within each row across b and c (the three 
rows correspond to the GWAS of general risk tolerance, adventurousness (n =  557,923), and the first PC of the four risky behaviors (n =  315,894)).
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tagged most of the genetic variants typically used to test the 15 genes. 
Across one SNP-based test and two gene-based tests, we found 
no evidence of non-negligible associations between those genes 
and general risk tolerance (Fig. 1c and Supplementary Table 16). 
(We note, however, that some brain regions identified in analy-
ses reported below are areas where dopamine and serotonin play 
important roles.)
Second, we performed a MAGMA30 gene analysis to test each 
of ~18,000 protein-coding genes for association with general risk 
tolerance (Supplementary Note). After Bonferroni correction, 285 
genes were significant (Supplementary Fig. 10 and Supplementary 
Table 17). To gain insight into the functions and expression patterns 
of these 285 genes, we looked them up in the Gene Network31 coex-
pression database.
Third, to identify relevant biological pathways and identify tis-
sues in which genes near general-risk-tolerance-associated SNPs 
were expressed, we applied the software tool DEPICT32 to the SNPs 
with P values less than 10–5 in our GWAS of general risk tolerance 
(Supplementary Note).
Both the Gene Network and the DEPICT analyses separately 
pointed to a role for glutamate and GABA neurotransmitters, which 
are the main excitatory and inhibitory neurotransmitters in the 
brain, respectively33 (Fig. 3a and Supplementary Tables 18 and 19). 
To our knowledge, with the exception of a recent study34 prioritiz-
ing a much larger number of genes and pathways, no published 
large-scale GWAS of cognition, personality, or neuropsychiatric 
phenotypes has indicated clear roles both for glutamate and GABA 
(although glutamatergic neurotransmission has been implicated 
in recent GWAS of schizophrenia35 and major depression36). Our 
results suggest that the balance between excitatory and inhibitory 
neurotransmission may contribute to variation in general risk toler-
ance across individuals.
The Gene Network and the DEPICT tissue enrichment analyses 
also both separately pointed to enrichment of the prefrontal cortex 
and the basal ganglia (Fig. 3b and Supplementary Tables 18, 20, and 
21). The cortical and subcortical regions highlighted by DEPICT 
include some of the major components of the cortical-basal ganglia 
circuit, which is known as the reward system in human and nonhu-
man primates and is critically involved in learning, motivation, and 
decision-making, notably under risk and uncertainty37,38. We caution, 
however, that our results do not point exclusively to the reward system.
Finally, we used stratified LD score regression39 to test for the 
enrichment of SNPs associated with histone marks in ten tissue or 
cell types (Supplementary Note). Central nervous system tissues 
were the most enriched, accounting for 44% (s.e. = 3%) of the heri-
tability while composing only 15% of the SNPs (Supplementary Fig. 
11a and Supplementary Table 22). Immune/hematopoietic tissues 
were also significantly enriched. Although a role for the immune 
system in modulating risk tolerance is plausible given prior evi-
dence of its involvement in several neuropsychiatric disorders35,36, 
future work is needed to confirm this result and to uncover specific 
pathways that might be involved.
Discussion
Our results provide insights into biological mechanisms that influ-
ence general risk tolerance. Our bioinformatics analyses point to the 
role of gene expression in brain regions that have been identified by 
neuroscientific studies on decision-making, notably the prefrontal 
cortex, basal ganglia, and midbrain, thereby providing convergent 
evidence with that from neuroscience37,38. Yet our analyses failed to 
find evidence for the main biological pathways that had been previ-
ously hypothesized to influence risk tolerance. Instead, our analyses 
implicate genes involved in glutamatergic and GABAergic neuro-
transmission, which were heretofore not generally believed to play a 
noteworthy role in risk tolerance.
Although our focus was on the genetics of general risk toler-
ance and risky behaviors, environmental and demographic factors 
accounted for a substantial share of these phenotypes’ variation. We 
observed sizeable effects of sex and age on general risk tolerance 
in the UKB data (Supplementary Fig. 4), and life experiences have 
been shown to affect both measured risk tolerance and risky behav-
iors (see, for example, refs. 40,41). The GWAS results that we gener-
ated should allow researchers to construct and use polygenic scores 
of general risk tolerance to measure how environmental, demo-
graphic, and genetic factors interact with one another.
For the behavioral sciences, our results bear on an ongoing 
debate about the extent to which risk tolerance is a ‘domain-general’ 
as opposed to a ‘domain-specific’ trait. Low phenotypic correlations 
in risk tolerance across decision-making domains have been inter-
preted as supporting the domain-specific view22,23. Across the risky 
behaviors we study, we found that the genetic correlations were con-
siderably higher than the phenotypic correlations (even after the lat-
ter were corrected for measurement error) and that many lead SNPs 
were shared across our phenotypes. These observations suggest that 
the low phenotypic correlations across domains are due to envi-
ronmental factors that dilute the effects of a genetically influenced 
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Fig. 2 | Genetic correlations with general risk tolerance. The genetic 
correlations were estimated with bivariate LD score regression9. Error bars 
show 95% confidence intervals. For the supplementary phenotypes and 
the additional risky behaviors, green bars represent significant estimates 
with the expected signs, where higher risk tolerance was associated with 
riskier behavior. For the other phenotypes, blue bars represent significant 
estimates. Light green and light blue bars represent genetic correlations 
that were statistically significant at the 5% level, and dark green and dark 
blue bars represent correlations that were statistically significant after 
Bonferroni correction for 35 tests (the total number of phenotypes tested). 
Gray bars represent correlations that were not statistically significant at the 
5% level. The two dotted vertical lines indicate genetic correlations of –0.5 
and 0.5, respectively. All significance tests are two sided.
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Fig. 3 | Results from selected biological analyses. a, DEPICT gene-set enrichment diagram. We identified 93 reconstituted gene sets that were significantly 
enriched (FDR < 0.01) for genes overlapping DEPICT-defined loci associated with general risk tolerance; according to the affinity propagation method42, these 
were grouped into the 13 clusters displayed in the graph. Each cluster was named after its exemplary gene set, as chosen by the affinity propagation tool, and 
each cluster’s color represents the permutation P value of its most significant gene set. The ‘synapse part’ cluster includes the gene set ‘glutamate receptor 
activity’, and several members of the ‘GABAA receptor activation’ cluster are defined by GABA signaling. Overlap between the named representatives of two 
clusters is represented by an edge. Edge width represents the Pearson correlation ρ between the two respective vectors of gene membership scores (ρ <  0.3, no 
edge; 0.3 ≤ ρ <  0.5, thin edge; 0.5 ≤ ρ <  0.7, intermediate edge; ρ ≥ 0.7, thick edge). b, Results of DEPICT tissue enrichment analysis using GTEx data. The panel 
shows whether the genes overlapping DEPICT-defined loci associated with general risk tolerance were significantly overexpressed (relative to genes in random 
sets of loci matched by gene density) in various tissues. Tissues are grouped by organ or tissue type. The orange bars correspond to tissues with significant 
overexpression (FDR < 0.01). The y axis is the significance on a − log10 scale. The Supplementary Note provides additional details.
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Methods
This article is accompanied by a Supplementary Note with further details. Further 
information on experimental design is also available in the Life Sciences Reporting 
Summary linked to this article.
Phenotype definitions, GWAS, quality control, and meta-analysis. For our 
discovery GWAS of general risk tolerance (n = 939,908), we performed a sample-
size-weighted meta-analysis of results from the UKB (n = 431,126) and a sample 
of research participants from 23andMe (n = 508,782). For our replication GWAS 
of general risk tolerance (n = 35,445), we performed a sample-size-weighted meta-
analysis of results from ten smaller cohorts from seven studies: Army STARRS, 
BASE-II, NFBC 1966, RSIII, STR, UKHLS, and VIKING. The exact measures for 
the general risk tolerance phenotype vary across cohorts in wording and number 
of response categories, but all measures are similar and ask about one’s tendency, 
preparedness, or willingness to take risks in general (Supplementary Table 4).
For our GWAS of adventurousness, we analyzed data from a sample of research 
participants from 23andMe (n = 557,923). We analyzed responses to the question 
‘If forced to choose, would you consider yourself to be more cautious or more 
adventurous?’, with possible responses ranging from ‘(1) very cautious’ to ‘(5) very 
adventurous’. For our GWAS of three of the four risky behaviors—automobile 
speeding propensity (n = 404,291), drinks per week (n = 414,343), and number 
of sexual partners (n = 370,711)—and for the first PC of the four risky behaviors 
(n = 315,894), we analyzed UKB data. For the remaining risky behavior, ever 
smoker (n = 518,633), we meta-analyzed GWAS results from the UKB and from 
the TAG Consortium43. Our automobile speeding propensity phenotype is based 
on responses to the question ‘How often do you drive faster than the speed limit 
on the motorway?’, with possible responses ranging from ‘(1) never/rarely’ to 
‘(4) most of the time’. We dropped individuals who answered ‘(5) do not drive 
on the motorway’, and then we normalized the categorical variable for males and 
females separately. Our drinks per week phenotype was constructed on the basis 
of responses to a series of questions about drinking habits and is defined as the 
number of alcoholic drinks consumed per week. Our ever-smoker phenotype 
in the UKB is a dummy variable that was equal to one if a respondent reported 
being a current or previous smoker and zero if the respondent reported never 
smoking or only smoking once or twice; our ever smoker phenotype from the 
TAG Consortium is the consortium’s ‘smoking initiation’ phenotype (which 
TAG also refers to as ‘ever versus never regular smoker’)43. Our number of sexual 
partners phenotype is based on responses to the question ‘About how many sexual 
partners have you had in your lifetime?’; respondents who reported more than 
99 lifetime sexual partners were asked to confirm their responses. We assigned 
a value of zero to participants who reported having never had sex, and we again 
normalized this measure separately for males and females. Our first PC phenotype 
is the first PC obtained from a PC analysis in the UKB of the four risky behaviors 
(Supplementary Table 23). All seven phenotypes were coded such that higher 
phenotype values were associated with higher risk tolerance or risk taking. Table 1  
lists, for each GWAS, the datasets we analyzed and the GWAS sample size. The 
Supplementary Note and Supplementary Tables 4 and 5 provide additional details 
on the cohorts and phenotype definitions.
All GWAS were performed at the cohort level in European-ancestry subjects 
according to a prespecified and publicly archived analysis plan (see URLs). All 
GWAS included controls for the top ten (or more) PCs of the genetic relatedness 
matrix and for sex and birth year. Genotyping was performed by using a range of 
commercially available genotyping arrays. We applied extensive quality-control 
procedures to the cohort-level summary statistics, including but not limited to 
the EasyQC protocol developed by the GIANT consortium44. We used Haplotype 
Reference Consortium v.1.1 data to construct our main reference panel, which 
we used for quality control of the GWAS summary statistics and to determine 
the independence of significant loci. For the 23andMe and UKB cohorts, only 
SNPs with minor allele frequency (MAF) greater than 0.001 were analyzed. All 
meta-analyses were restricted to SNPs with a sample size greater than half of the 
maximum sample size across all the SNPs in the GWAS. In total, 9,284,738 SNPs 
were analyzed in the discovery GWAS of general risk tolerance; 9,339,358 SNPs 
were analyzed in the GWAS of adventurousness; and ~11,515,000 SNPS were 
analyzed in the GWAS of the four risky behaviors and their first PC. To adjust 
standard errors for the possible effects of population stratification, we inflated 
them by the square root of the estimated intercept from an LD score regression 
(for the replication GWAS of general risk tolerance, which meta-analyzed different 
cohorts, we inflated them at the meta-analysis level). Additional details are 
provided in the Supplementary Note and Supplementary Tables 2 and 24–26.
To identify approximately independent lead SNPs, we applied a clumping 
algorithm to the GWAS results. Our clumping algorithm begins by selecting the 
SNP with the lowest P value as the lead SNP in the first clump and includes in the 
first clump all SNPs that have r2 greater than 0.1 with the lead SNP and that have 
a GWAS P value less than 1 × 10–4. Next, the SNP with the second-lowest P value 
outside the first clump becomes the lead SNP of the second clump, and the second 
clump is created analogously but using only the SNPs outside of the first clump. 
This process continues until every genome-wide-significant SNP (that is, every 
SNP with a GWAS P value less than 5 × 10–8) is either designated as a lead SNP 
or is clumped to another lead SNP. We also defined nonoverlapping, continuous 
genomic loci around the lead SNPs by using the locus definition of Ripke et al.45, 
and we performed COJO analyses12. Ripke et al. defined a locus as “the physical 
region containing all SNPs correlated at r2 > 0.6 with [one of the lead] SNPs,” and 
merged associated loci within 250 kb of each other. To define the set of distinct 
loci containing all the loci corresponding to the locus associations from across 
the seven GWAS, we pooled the loci corresponding to the locus associations and 
merged loci within 250 kb of each other. For the COJO analyses, for each of the 
seven main GWAS we restricted the analysis to the set of SNPs that (i) passed all 
GWAS quality-control filters and (ii) were located within the loci of the phenotype 
(which included all of the lead SNPs).
Supplementary Tables 3, 6, 7, and 27 report the lead SNPs, the loci, the results 
of the COJO analyses, and the results of a lookup of the lead SNPs in the NHGRI-
EBI GWAS Catalog database19 for our seven main GWAS; Supplementary Fig. 12 
shows the GWAS estimates of general-risk-tolerance lead SNPs in the 23andMe 
and UKB cohorts and in the replication GWAS, and the Supplementary Data show 
LocusZoom plots for all the loci identified in the seven GWAS.
Testing for population stratification. To assess the extent to which population 
stratification might have biased our GWAS estimates, we conducted three tests. 
First, we estimated LD score intercepts by using the summary statistics of the 
discovery and replication GWAS of general risk tolerance and of the GWAS of our 
four main risky behaviors and their first PC. Second, following Okbay et al.10,  
we conducted sign tests that compared the signs of the estimates from our 
discovery GWAS of general risk tolerance (but excluded all full siblings from 
the UKB cohort) to the signs of the estimates from within-family GWAS of 
general risk tolerance. If our discovery GWAS estimates were entirely driven by 
stratification, then the signs of the within-family estimates—which are immune 
to stratification—should be independent of the signs of the discovery GWAS 
estimates, in which case we would expect a sign concordance of roughly 50%. 
A higher degree of sign concordance would suggest that at least some of the 
signal from the GWAS comes from true genetic effects. Across four sign tests, we 
strongly rejected the null hypothesis of 50% sign concordance for all of the sign 
tests (P < 5 × 10−10 in all four tests), thus implying that at least some of the signal 
from the GWAS came from true genetic effects. Our third test of population 
stratification, the within-family regression test, compared both the signs and 
magnitudes of the discovery and within-family GWAS of general risk tolerance. 
The Supplementary Note, Supplementary Tables 28 and 29, and Supplementary 
Fig. 13 provide further details on the three tests and report their results. All three 
tests implied no more than low levels of population stratification.
Replication of the general-risk-tolerance lead SNPs and maxFDR calculation. 
To assess the credibility of the lead SNPs from our discovery GWAS of general 
risk tolerance, we compared those results with the estimates from our replication 
GWAS of general risk tolerance. (We did not attempt replication of the results 
of our six supplementary GWAS in independent data, because we did not have 
access to such data for these phenotypes.) We first filtered out SNPs with sample 
size less than one-half the maximum sample size in the replication GWAS. After 
we applied this filter, 122 of the 124 lead SNPs were directly available in the 
replication GWAS summary statistics, and one of the two remaining lead SNPs 
was well proxied by a SNP in high LD (r2 > 0.8) with it. For the resulting 123 SNPs, 
we conducted a (one-sided) binomial sign test to assess whether the directions 
(that is, the signs) of the effects of the lead SNPs were more concordant across the 
discovery and the replication GWAS than expected by chance. We also conducted 
a (one-sided) binomial test to assess whether a larger fraction of the lead SNPs 
was significant at the 5% level in one-sided tests in the replication GWAS than 
expected by chance. We then followed the procedure outlined by Okbay et al.46  
and conducted a Bayesian analysis to obtain estimates of the posterior 
distributions of the 123 SNPs’ true effect sizes (the βj values), given their GWAS 
estimates. We used the SNPs’ estimated posterior distributions to estimate their 
expected replication record in the two binomial tests and compared their actual 
and expected replication records.
To calculate the maxFDR, an upper bound on the FDR for a GWAS, we used 
the MTAG software15 and followed the methodology described in section 1.4.3 in 
the supplementary information of Turley et al.15. The maxFDR is defined as the 
maximum theoretical FDR over a range of possible fractions of null SNPs (πnull).
The Supplementary Note and Supplementary Fig. 3 provide additional details.
Estimation of genome-wide SNP heritability. We used the heritability estimator 
from summary statistics (HESS)47 method to estimate the genome-wide SNP 
heritability of our seven main phenotypes. For the results reported in Table 1, 
we used the summary statistics from the GWAS listed in the table for all 1000 
Genomes phase 3 SNPs with MAF greater than 0.05. We did not apply genomic 
control (GC) prior to estimating heritability with HESS. The Supplementary Note, 
Supplementary Table 30, and Supplementary Fig. 14 provide additional details 
and also report estimates of the SNP heritability of our seven main phenotypes 
estimated with the GCTA48, LD score regression, and HESS methods, using only 
summary statistics from the UKB GWAS for comparability across phenotypes and 
methods (except for adventurousness, which is not available in the UKB and for 
which we used the 23andMe summary statistics).
NatuRe GeNetics | www.nature.com/naturegenetics
ArticlesNature GeNetics
Genetic correlations. We used bivariate LD score regression9 to estimate genetic 
correlations between general risk tolerance and various phenotypes. We used the 
scores computed by Finucane et al.49, which are based on genotypic data from 
the European-ancestry samples in the 1000 Genomes Project and only HapMap3 
SNPs. As is common in the literature, we restricted our analyses to SNPs with 
MAF > 0.01. We used the summary statistics of the meta-analysis combining our 
discovery and replication GWAS of general risk tolerance to estimate genetic 
correlations with general risk tolerance, and we used the summary statistics of our 
GWAS of adventurousness, our four main risky behaviors, and their first PC to 
estimate genetic correlations with those phenotypes. For most other phenotypes, 
we used published GWAS results. We obtained the summary statistics from 
the GWAS of lifetime cannabis use24 and of ADHD50 from the International 
Cannabis Consortium and the Psychiatric Genomics Consortium, respectively. 
We conducted our own GWAS using the first release of the UKB data for five 
phenotypes: age first had sexual intercourse (n = 98,956), teenage conception 
among females (n = 40,077), use of sun protection (n = 111,560), household 
income (n = 97,059), and Townsend deprivation index score (n = 112,192). 
The sex-specific GWAS of general risk tolerance used to estimate the genetic 
correlation between males and females were conducted in the full release of UKB 
data, separately for males and females, by following the same methodology and 
quality-control protocol as for our other GWAS in the full release of UKB data. 
The Supplementary Note and Supplementary Tables 9 and 31 provide additional 
details. In addition, the Supplementary Note, Supplementary Table 32, and 
Supplementary Fig. 15 report the results of proxy-phenotype analyses in which 
we examined whether the general-risk-tolerance lead SNPs tended to also be 
associated with related phenotypes.
MTAG. We used MTAG15 to increase the precision of our estimates of the SNPs’ 
effects on general risk tolerance. We used as inputs the summary statistics of the 
meta-analysis combining our discovery and replication GWAS of general risk 
tolerance; the summary statistics of our GWAS of adventurousness, automobile 
speeding propensity, drinks per week, ever smoker, and number of sexual partners; 
and the summary statistics of a previously published GWAS on lifetime cannabis 
use51. Because SNPs that have no effect on one phenotype but a sizeable effect 
on another can bias MTAG results, we excluded from this analysis SNPs in the 
proximity of several genes implicated in biological processes likely to be specific 
to only one of the phenotypes. Specifically, we excluded all SNPs located within 
1 Mb of the genes CHRNA5 and CHRNB3 (nicotinic receptors), CNR1 and CNR2 
(cannabinoid receptors), and ADH1B (alcohol dehydrogenase). We imposed a 
MAF filter of 0.01 and a sample-size filter that selected, for each GWAS, the SNPs 
with sample sizes larger than two-thirds of the ninth decile of the GWAS’s sample 
size. MTAG limited the analysis to the 5,869,552 SNPs analyzed in all GWAS (and 
that satisfied these filters). To identify approximately independent lead SNPs for 
general risk tolerance, we applied the clumping algorithm described above. The 
Supplementary Note, Supplementary Table 10, and Supplementary Fig. 7 provide 
further details.
Polygenic prediction. We assessed the predictive power of polygenic scores 
of general risk tolerance in six different validation cohorts: Add Health, HRS, 
NTR, STR, UKB-siblings, and Zurich. (The UKB-siblings cohort comprised 
all individuals with at least one full sibling in the UKB.) We constructed three 
polygenic scores. Our first two polygenic scores were constructed with the 
LDpred27 method, which accounts for the LD between SNPs. The first used the 
summary statistics from the meta-analysis of the discovery and replication GWAS 
of general risk tolerance, whereas the second used the MTAG summary statistics. 
(The LDpred method relies on a Gaussian mixture weight that corresponds to the 
assumed fraction of SNPs that are causal. For each of our first two polygenic scores, 
we first generated LDpred scores for each of the following mixture weights: 1, 0.3, 
0.1, 0.03, 0.01, 0.003, 0.001, 0.0003, and 0.0001 (ref. 52). The LDpred score results 
presented in this paper for our first two polygenic scores are for the scores based 
on a Gaussian mixture weight of 0.3 (our ‘preferred score’), which consistently 
performed well across cohorts and phenotypes.) Our third polygenic score was 
constructed with the classical method, which simply weights SNPs by their GWAS 
effect size53,54, using the summary statistics from the meta-analysis of the discovery 
and replication GWAS of general risk tolerance.
We used the subset of all the SNPs (that is, we did not impose a P-value 
threshold) in the HapMap consortium phase 3 release55 with an imputation quality 
of more than 0.7 to generate all three scores. For every validation cohort that was 
also included in the discovery or replication GWAS or in the MTAG analysis, we 
reran the GWAS and MTAG analyses without the validation cohort to generate 
the summary statistics we used to construct the scores. Owing to data access 
limitations, the 23andMe cohort could not be included in the meta-analysis whose 
summary statistics we used to construct the polygenic scores in the NTR, STR, and 
Zurich cohorts. The second polygenic score (using the MTAG summary statistics) 
was constructed only for the Add Health, HRS, and UKB-siblings cohorts.
Our measure of a score’s predictive power for a predicted phenotype is the 
incremental R2 (or incremental pseudo-R2) from adding the score to a regression 
of the phenotype on controls for sex, birth year, birth year squared, and birth year 
cubed, as well as the interactions between sex and the three birth year variables, 
and the first ten principal components of the genetic relatedness matrix. We used 
the bootstrap method with 1,000 iterations to estimate the ninety-fifth-percentile 
confidence intervals for the incremental R2 estimates. For continuous phenotypes, 
we estimated ordinary least squares regressions; for binary phenotypes (for 
example, ever smoker), we estimated probit models; and for censored phenotypes 
(for example, equity share, which is non-negative), we estimated tobit models. For 
binary and censored phenotypes, we used McFadden’s pseudo-R2 to calculate the 
incremental pseudo-R2.
The Supplementary Note provides additional details, including a description 
of how the predicted phenotypes were constructed. Results are presented in 
Supplementary Figs. 8 and 9 and Supplementary Tables 11–14.
Biological annotation: testing hypotheses about specific genes and gene sets. 
We conducted a comprehensive review of the literature on biological pathways that 
have been hypothesized to influence risk tolerance. The 132 articles identified by 
the review are compiled in Supplementary Table 1. The Supplementary Note and 
Supplementary Tables 15, 16, 33, and 34 provide further details and report the 
results of the various analyses we conducted to assess whether the pathways and 
genes that have previously been hypothesized to relate to risk tolerance do indeed 
show evidence of association with risk tolerance.
Biological annotation: additional bioinformatics analyses. We conducted a 
series of additional bioinformatics analyses using the results of the combined 
meta-analysis of our discovery and replication GWAS of general risk tolerance. 
We conducted a gene analysis with MAGMA30 to test each of 18,224 genes for 
association with general risk tolerance in a hypothesis-free manner (the 18,224 
genes are the set of all genes containing at least one SNP in our combined meta-
analysis results). We used our main reference panel to estimate LD. Bonferroni 
correction was applied to account for multiple testing, counting each gene as an 
independent test. We then used the Gene Network31 co-expression database to gain 
insight into the functions of the significant MAGMA genes.
We also used DEPICT32 (release 194) to prioritize tissues, gene sets, and genes 
implicated by our GWAS results. Only SNPs with GWAS P values less than 10–5 
were used as input, and DEPICT-defined loci were defined by clumping these 
SNPs (clumping parameters used for this analysis are shown in the Supplementary 
Note). Locus boundaries were then defined by using a LD r2 threshold of 0.5, and 
overlapping loci were merged, yielding 464 autosomal loci comprising 1,060 genes.
To partition the SNP-based heritability of general risk tolerance, we used stratified 
LD score regression49, following the procedure described by Finucane et al.49.  
We estimated stratified LD score regressions both for the functional genomic 
regions of the ‘baseline model’ and for the tissue-level annotations provided by 
Finucane et al. To correct for multiple hypothesis testing, we applied a Bonferroni 
correction for 52 two-sided tests in the baseline model (that is, for 52 annotations) 
and for ten two-sided tests in the tissue type models (that is, for ten tissue types).
The Supplementary Note, Supplementary Tables 17–22 and 35–39, and 
Supplementary Figs. 10, 11, and 16 provide further details and report the results of 
these and other bioinformatics analyses, including a transcriptome-wide analysis 
with summary-based Mendelian randomization (SMR)56, and an ascertainment 
of whether the lead SNPs and their LD partners (SNPs with an r2 > 0.6 with 
a lead SNP and no more than 250 kb from it) are protein-altering variants or 
are associated with cis gene expression in distinct human tissues, among other 
analyses. The Supplementary Note also highlights the most important results of the 
bioinformatics analyses and summarizes the conclusions we derive from them.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
GWAS summary statistics can be downloaded from http://www.thessgac.org/
data. SNP-level summary statistics from analyses based entirely or in part on 
23andMe data can only be reported for up to 10,000 SNPs. For general risk 
tolerance, we provide association results for all SNPs that passed quality-control 
filters in a GWAS meta-analysis of general risk tolerance that excludes the research 
participants from 23andMe; we also provide association results from the complete 
GWAS (which includes data from 23andMe) for all lead SNPs identified in our 
discovery GWAS and MTAG analysis of general risk tolerance and for the 4,000 
most significant SNPs in the meta-analysis of the discovery and replication GWAS 
of risk tolerance. For adventurousness, we provide association results from the 
complete GWAS (which includes only data from 23andMe) for all lead SNPs and 
for the next 4,000 most significant SNPs. For automobile speeding propensity, 
drinks per week, ever smoker, number of sexual partners, and the first PC of the 
four risky behaviors, we provide association results from the complete GWAS for 
all SNPs that passed quality-control filters. Contact information for the cohorts 
included in this paper can be found in the Supplementary Note.
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Life Sciences Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life 
science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list 
items might not apply to an individual manuscript, but all fields must be completed for clarity. 
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research 
policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Please do not complete any field with "not applicable" or n/a.  Refer to the help text for what text to use if an item is not relevant to your study. 
For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.
    Experimental design
1.   Sample size
Describe how sample size was determined. The appropriate sample size was determined based on power calculations reported in the 
preregistered analysis plan on Open Science Framework (https://osf.io/cjx9m/). That 
information is also reported in Supplementary Note section 2: 
"The analysis plan included power calculations assuming that 100,000 individuals in the UKB 
answered “Yes” (“cases”) to the general-risk-tolerance question, and 270,000 individuals 
answered “No” (“controls”). Under this assumption, our study would have 73% power to 
detect single nucleotide polymorphisms (SNPs) with a minor allele frequency (MAF) of 0.3 
and an odds ratio of 1.05 with a genome-wide significance threshold of P = 5×10–8." 
Ultimately, for the general risk tolerance phenotype, we combined data from the UKB, from a 
sample of research participants from 23andMe, and from 10 smaller replication cohorts. 
2.   Data exclusions
Describe any data exclusions. Exclusion criteria were specified in the preregistered analysis plan on Open Science 
Framework. That information is also reported in Supplementary Note section 2: 
"The analysis plan instructed all cohorts to limit the analysis to individuals of European 
ancestry, to exclude individuals with missing covariates, to remove samples that displayed a 
SNP call rate of less than 95%, and to apply cohort-specific standard quality control filters 
before imputation."
3.   Replication
Describe the measures taken to verify the reproducibility 
of the experimental findings.
Supplementary Information section 5 reports holistic, out-of-sample replication in ~35,000 
individuals. Also, we test whether polygenic scores have predictive power in multiple 
independent prediction cohorts (Supplementary Information section 10). In all cases, the 
replication record is strong.
4.   Randomization
Describe how samples/organisms/participants were 
allocated into experimental groups.
Not relevant because the study is not experimental.
5.   Blinding
Describe whether the investigators were blinded to 
group allocation during data collection and/or analysis.
Not relevant because the study is not experimental.
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
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6.   Statistical parameters 
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the 
Methods section if additional space is needed). 
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same 
sample was measured repeatedly
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
Test values indicating whether an effect is present 
Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
   Software
Policy information about availability of computer code
7. Software
Describe the software used to analyze the data in this 
study. 
The URLs section in the main text contains links to software used in this study, and the 
Supplementary Note describes the software that were used for the various analyses. In 
summary: 
Cohort-level imputation was performed with MaCH/Minimac, BEAGLE, IMPUTE2/4, PBWT, 
and ShapeIT. 
Genetic data was managed with QCtool and BCFtools. 
GWAS association was performed with PLINK, SNPtest, Mach2QTL, GCTA, BOLT-LMM, 
regscan, and R. 
Meta-analyses were performed with METAL.  
QC of GWAS summary statistics was performed with EasyQC and R.  
LD score regressions were done using ldsc v1.0.0 and Python.  
Clumping was performed with Plink, 1.90b3p.  
Conditional association analysis was performed with GCTA. 
Polygenic score weights were generated using LDpred v0.9.09.  
Polygenic scores were calculated with PLINK. 
SNP heritability was estimated with ldsc v1.0.0, HESS, and GCTA. 
Biological annotation and gene-based analyses were conducted using SMR, DEPICT 
(downloaded Feb 2015), MAGMA v1.06b. 
MTAG analyses were conducted using the MTAG software v1.0.1. 
Auxiliary statistical analyses were performed with Python, STATA, and R.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made 
available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for 
providing algorithms and software for publication provides further information on this topic.
   Materials and reagents
Policy information about availability of materials
8.   Materials availability
Indicate whether there are restrictions on availability of 
unique materials or if these materials are only available 
for distribution by a third party.
No unique materials were used.
9.   Antibodies
Describe the antibodies used and how they were validated 
for use in the system under study (i.e. assay and species).
No antibodies were used.
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10. Eukaryotic cell lines
a.  State the source of each eukaryotic cell line used. No eukaryotic cell lines were used
b.  Describe the method of cell line authentication used. No eukaryotic cell lines were used.
c.  Report whether the cell lines were tested for 
mycoplasma contamination.
No eukaryotic cell lines were used.
d.  If any of the cell lines used are listed in the database 
of commonly misidentified cell lines maintained by 
ICLAC, provide a scientific rationale for their use.
No cell lines were used. 
    Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
11. Description of research animals
Provide all relevant details on animals and/or 
animal-derived materials used in the study.
No research animals were used in this study.
Policy information about studies involving human research participants
12. Description of human research participants
Describe the covariate-relevant population 
characteristics of the human research participants.
Analyses were conducted on GWAS summary statistics. References to the studies that report 
covariate-relevant population characteristics are in Supplementary Tables 4-5.
